Drug Research
InSilicoTrials and Galileo Research announce their partnership
Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the healthcare sector, and Galileo Research established a partnership to apply...
Drug Research
Velocity Clinical Research’s multi-site acquisitions signal new frontier for clinical site management industry
Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds 11 sites to Velocity’s existing 18, making it the largest fully integrated site management...
Drug Research
FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar
Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...
Drug Research
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. announced a strategic alliance.
Under the terms of the agreement, BBL will offer approximately...
Drug Research
Frontage Expands Early Drug Discovery Services through the Acquisition of Heyan Biotech
Frontage Shanghai announced the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic...
Drug Research
Recro and BioCorRx expand partnership for OUD treatment
Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc., a developer and provider of advanced solutions in the treatment of substance use...
Drug Research
Repligen and Navigo GmbH Announce Launch of Industry First Protein A Ligand for Purification of pH Sensitive Antibodies
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
